TOPIC 324 PHASE I; NOVEL IMAGING AGENTS TO EXPAND THE CLINICAL TOOL KIT FOR CANCE

靶向癌症分子成像对于更好的个性化医疗至关重要，但需要能够识别关键分子表面细胞标记的新型显像剂。Her2在20-30%的乳腺癌中过表达，是赫赛汀的靶点，但目前还没有Her2分子显像剂被临床批准。我们建议使用扫描非天然蛋白酶抗性（SUPR）肽来开发一种新的her2特异性PET/CT放射性示踪剂。SUPR肽具有抗体样亲和力，抗蛋白水解和代谢修饰，并能快速从体循环中清除，使其成为理想的显像剂。首先，用近红外光学染料修饰的抗her2 SUPR肽将被筛选用于her2特异性肿瘤摄取小鼠。然后我们将合成[18F]标记的SUPR肽，通过PET/CT对her2过表达的肿瘤进行成像。EvoRx Technologies将与MD Anderson癌症中心合作，将SUPR肽快速转化为强大的核成像工具，推进乳腺癌的个性化治疗。

Targeted molecular imaging of cancer is vital for better personalized medicine, but requires novel imaging agents that recognize key molecular surface cell markers. Her2 is overexpressed in 20-30% of breast cancer and is targeted by Herceptin, yet no molecular imaging agent for Her2 is clinically approved. We propose to use Scanning Unnatural Protease Resistant (SUPR) peptides to develop a novel Her2-specific radiotracer for PET/CT. SUPR peptides show antibody-like affinities, resistance to proteolytic and metabolic modification, and rapid clearance from systemic circulation, making them ideal imaging agents. First, Anti-Her2 SUPR peptides modified with a near-infrared optical dye will be screened for Her2-specific tumor uptake mice. We will then synthesize [18F]-labeled SUPR peptides to image Her2-overexpressing tumors by PET/CT. EvoRx Technologies will collaborate with the MD Anderson Cancer Center to rapidly translate SUPR peptides into a powerful nuclear imaging tool, advancing the personalized treatment of breast cancer.